Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CEMIPLIMAB Cause Chronic obstructive pulmonary disease? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Chronic obstructive pulmonary disease have been filed in association with CEMIPLIMAB (LIBTAYO). This represents 0.6% of all adverse event reports for CEMIPLIMAB.

6
Reports of Chronic obstructive pulmonary disease with CEMIPLIMAB
0.6%
of all CEMIPLIMAB reports
1
Deaths
3
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From CEMIPLIMAB?

Of the 6 reports, 1 (16.7%) resulted in death, 3 (50.0%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CEMIPLIMAB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does CEMIPLIMAB Cause?

Fatigue (68) Pyrexia (49) Pneumonia (41) Dyspnoea (40) Pneumonitis (38) Off label use (35) Diarrhoea (34) Rash (34) Cytokine release syndrome (33) Pain (33)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which CEMIPLIMAB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

CEMIPLIMAB vs CEMIPLIMAB-RWLC CEMIPLIMAB vs CENEGERMIN-BKBJ CEMIPLIMAB vs CENOBAMATE CEMIPLIMAB vs CEPHALEXIN CEMIPLIMAB vs CERITINIB

Related Pages

CEMIPLIMAB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease CEMIPLIMAB Demographics